Atossa Therapeutics Inc ATOS:NASDAQ

RT Quote | NASDAQ | USD
Last | 06/30/22 EDT
1.09quote price arrow down-0.07 (-6.03%)
Volume
1,000,648
52 week range
0.84 - 7.15
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.09
  • 52 Week High7.15
  • 52 Week High Date07/14/21
  • 52 Week Low0.84
  • 52 Week Low Date05/25/22

Key Stats

  • Market Cap138.02M
  • Shares Out126.62M
  • 10 Day Average Volume2.86M
  • Dividend-
  • Dividend Yield-
  • Beta1.80
  • YTD % Change-31.88

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.09
  • 52 Week High7.15
  • 52 Week High Date07/14/21
  • 52 Week Low0.84
  • 52 Week Low Date05/25/22
  • Market Cap138.02M
  • Shares Out126.62M
  • 10 Day Average Volume2.86M
  • Dividend-
  • Dividend Yield-
  • Beta1.80
  • YTD % Change-31.88

RATIOS/PROFITABILITY

  • EPS (TTM)-0.18
  • P/E (TTM)-6.15
  • Fwd P/E (NTM)-4.84
  • EBITDA (TTM)-21.722M
  • ROE (TTM)-15.97%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/11/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Atossa Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene...
Steven Quay M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Kyle Guse Esq., J.D.
Chief Financial Officer, General Counsel, Secretary
Address
107 Spring St
Seattle, WA
98104-1005
United States